In-depth: After a rough 17 years, is Biovac finally on track?
South Africa has struggled to secure adequate stock of urgently needed COVID-19 vaccines. This has raised questions about the state of the country’s local vaccine manufacturing capacity and why, after almost two decades of government support, South Africa’s partially state-owned vaccine manufacturer Biovac is not better positioned to respond to the pandemic. Catherine Tomlinson investigates.
